Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KetaMist
- Development stage
- Preclinical
- Lead developer
- PharmaTher
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
KetaMist is a proprietary, patient-controlled, and needle-free ketamine delivery platform developed for the treatment of treatment-resistant depression (TRD) and other neuropsychiatric and chronic pain conditions. Developed by Dr. Curtis W. Cassidy of Cassidy Psychiatry and later co-developed in collaboration with PharmaTher Holdings, KetaMist utilizes a nebulizer system to deliver racemic ketamine via inhalation. This method allows for personalized, real-time dose adjustments and patient-controlled administration under medical supervision, offering a non-invasive and cost-effective alternative to traditional intravenous infusions or nasal sprays. Ketamine acts primarily as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, enhancing glutamate signaling and promoting neuroplasticity to provide rapid antidepressant and analgesic effects.
- Brand names
- KetaMist
02
Targets
AMPAR (AMPA receptor)NTRK2 (Tropomyosin-related kinase receptor type B)mTOR (Mammalian target of rapamycin kinase)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on KetaMist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KetaMist.